Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1

Hiyama, Eiso; Hiyama, Keiko; Ohtsu, Kazuhiro; Yamaoka, Hiroaki; Fukuba, Ikuko; Matsuura, Yuichiro; Yokoyama, Takashi

doi:10.1002/1096-911x(20010101)36:1<67::aid-mpo1017>3.3.co;2-j

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large deletion in chromosome 1p was detected in 36 samples (18%), including the common region of deletion at 1p36 [16]. There was a significant association between 1p loss and MYCN amplification (M type) ( P b .001).…”

Section: Resultsmentioning

confidence: 96%

Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients

Hiyama

Yamaoka

Kamimatsuse

et al. 2006

Journal of Pediatric Surgery

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 96%

Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients

Hiyama

Yamaoka

Kamimatsuse

et al. 2006

Journal of Pediatric Surgery

Self Cite

View full text Add to dashboard Cite

“…The markers D1S199 and D1S1676 limit the last preferentially deleted region. Other studies suggested the presence of a TSG on 1p36.1 locus, not only in OSCC (9), but also in cervical cancer (24) and neuroblastoma (25). It has been recently shown that Rap1GAP gene, which is located in this region, is a putative TSG in pancreatic cancer (26).…”

Section: Discussionmentioning

confidence: 99%

Fine deletion analysis of 1p36 chromosomal region in oral squamous cell carcinomas

Lefeuvre

Gündüz

Nagatsuka

et al. 2008

J Oral Pathology Medicine

View full text Add to dashboard Cite

Materials and Methods:Paired samples of DNA extracted from 27 Japanese patients with OSCC were used. The samples were amplified by polymerase chain reaction (PCR) with 9 microsatellite markers selected from the literature which covers the lp36 region. The amplified samples were subject to polyacrylamide gel electrophoresis, stained with silver staining and used for loss of heterozygosity (LOB) analysis.Results: LOB was found at least in one locus in 85% of the investigated cases. The markers which gave the higher rates of LOB were DlS228 (38%), DlS199 (28%), DlS243 (25%), DlS450 (25%), DlS1676 (23%) and DlS468 (22%). We have identified 3 regions which are frequently deleted. They are region 1 (DlS468-DlS243), region 2 (DlS450-DlS228) and region 3 (DlS199-DlS1676).All of these regions harbor genes which could be candidate TSG as RIZ, p73, UBE4B, Rap 1GAP, EPHB2 or RUNX3. Moreover, in region 2, LOH only with the marker DlS228 was obtained in 22% of the case, so TSG located in region 2 are of special interest as they could be involved in early events of OSCC carcinogenesis.At the opposite, the markers DlS199 and DlS1676, which delimit the region~, do not shown LOH alone at the exception of 1 case, so it is possible that TSG of this region are related with later event of carcinogenesis in this type of cancer. Conclusions:We have localized 3 areas in 1p36 region which are frequently deleted in OSCC patients. All theses regions possess genes which could be candidate TSG involved in OSCC carcinogenesis. Further studies are needed for the clarification of the role of these genes in OSCe.

show abstract

“…Thus, in the present study, we analyzed this model without clinicopathological factors. Furthermore, triploidy, a well-known favorable factor is considered to be one of the major mechanisms to alter the switch towards regression or differentiation [18,19], and we also excluded the number of alleles in this model. It is well known that the MYCN gene is sometimes amplified in unfavorable neuroblastoma, and MYCN amplified tumors are rarely detected in infancy [20], suggesting that the MYCN gene may be a representative oncogene in neuroblastoma.…”

Section: Discussionmentioning

confidence: 99%

Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification

et al. 2007

Self Cite

View full text Add to dashboard Cite

Neuroblastoma is a heterogeneous tumor and that may have a favorable or unfavorable prognosis. In Japan, a nation-wide neuroblastoma mass-screening (MS) project assessed 6-month-old infants between 1985 and 2003, and almost all neuroblastomas, including regressing or maturing tumors were thought to be detected in this period. To evaluate the heterogeneity of neuroblastoma subgroups, we analyzed patients with neuroblastoma who had been diagnosed during this period. The clinical courses of 4,209 patients with neuroblastoma, including 1,560 MS detected patients, whose tumors had been diagnosed between 1971 and 1995 were registered. The 2,520 cases registered between 1985 and 1995 were compared to 1,050 cases registered between 1971 and 1980 and analyzed by a multi-gene target model to determine the age distribution of neuroblastoma incidence. We hypothesized that three target genes were responsible for the progression of neuroblastoma: one pair of tumor suppressor gene alleles, one oncogene, and one gene controlling regression/differentiation. This simulation study revealed that the age distribution at initial diagnosis of neuroblastoma was divided into four groups based on post-fertilization age: 20-40, 40-50, 60-90, and 160-200 weeks. Since neuroblatoma in the first group occurred prenatal, post-natal clinical neuroblastoma can be classified into three age groups: 0-6 months, 1-2 years, and 3-4 years. The 0- to 6-month group consisted of mostly benign tumors, and the two older groups had predominantly malignant phenotypes. Our proposed model could explain qualitatively the distribution of neuroblastoma consisting of one subgroup with a favorable prognosis and two subgroups with unfavorable prognosis. For clinically relevant risk stratification, an age cutoff should be considered by the age distribution of these heterogeneous subgroups.

show abstract

Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1

Cited by 4 publications

References 0 publications

Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients

Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients

Fine deletion analysis of 1p36 chromosomal region in oral squamous cell carcinomas

Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification

Contact Info

Product

Resources

About